Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003
- 10 October 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (29) , 4771-4776
- https://doi.org/10.1200/jco.2008.17.0662
Abstract
Purpose S0003 was a phase III trial of carboplatin/paclitaxel with or without the hypoxic cytotoxin tirapazamine in patients with advanced or metastatic non–small-cell lung cancer (NSCLC). We inves...This publication has 57 references indexed in Scilit:
- The Role of Osteopontin in Tumor Progression and Metastasis in Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Elevated plasma osteopontin associated with gastric cancer development, invasion and survivalGut, 2007
- Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancerLung Cancer, 2007
- Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Plasma Osteopontin Is an Independent Prognostic Marker for Head and Neck CancersJournal of Clinical Oncology, 2006
- Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast CancerClinical Cancer Research, 2006
- Overexpression of Osteopontin Is Associated with More Aggressive Phenotypes in Human Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissuesBlood, 2004
- Tumor angiogenesis of non–small cell lung cancerMicroscopy Research and Technique, 2003
- Hypoxia-specific cytotoxins in cancer therapySeminars in Radiation Oncology, 1996